Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Y+L amino acid transporter 1 (encoded by SLC7A7) is the light subunit of a sodium-independent, heterodimeric cationic amino acid transporter, which associates with the heavy chain SLC3A2 to form system y+L. This system facilitates the bidirectional exchange of cationic amino acids (notably lysine, arginine, ornithine) and large neutral amino acids across epithelial cell membranes in the intestine and kidney, playing an essential role in amino acid homeostasis. Mutations in SLC7A7 disrupt this transport, causing lysinuric protein intolerance (LPI), an autosomal recessive disorder with symptoms derived from defective absorption and reabsorption of basic amino acids. Beyond its role in amino acid transport, SLC7A7 also modulates immune responses in monocytes/macrophages and is implicated in disease states such as tumor progression and disorders of pregnancy[1][2][4][5][6].
Substrate competition for transport (as in high-dose amino acid supplementation); Restoration or bypassing of defective transport function (in LPI via therapeutic diet)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Y+L amino acid transporter 1 (SLC7A7).